

Peter R Rossing

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3128695/peter-r-rossing-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

566
papers

27,743
citations

82
h-index

147
g-index

633
ext. papers

36,676
ext. citations

7.6
avg. IF

7.18
L-index

#	Paper	IF	Citations
566	Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study.. <i>Diabetes Care</i> , 2022 ,	14.6	3
565	Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions.. <i>Kidney International Reports</i> , 2022 , 7, 699-707	4.1	1
564	Quetelet (Body Mass) Index and Effects of Dapagliflozin in CKD.. <i>Diabetes, Obesity and Metabolism</i> , 2022 ,	6.7	1
563	Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy.. <i>Kidney International Reports</i> , 2022 , 7, 36-45	4.1	11
562	Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial. <i>Diabetes, Obesity and Metabolism</i> , 2022 , 24, 125-134	6.7	5
561	The Kidney Protective Effects of the Sodium-Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists.. <i>Kidney International Reports</i> , 2022 , 7, 436-443	4.1	2
560	Clinical perspective-evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes.. <i>Kidney International Supplements</i> , 2022 , 12, 27-35	6.3	4
559	Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes.. <i>Cardiovascular Diabetology</i> , 2022 , 21, 50	8.7	1
558	Cardiovascular Autonomic Neuropathy in Type 1 Diabetes Is Associated With Disturbances in TCA, Lipid, and Glucose Metabolism.. <i>Frontiers in Endocrinology</i> , 2022 , 13, 831793	5.7	0
557	Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.. <i>Diabetologia</i> , 2022 , 1	10.3	1
556	Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 799915	5.6	0
555	Precision diagnostic approach to predict 5-year risk for microvascular complications in type 1 diabetes.. <i>EBioMedicine</i> , 2022 , 80, 104032	8.8	1
554	Diabetic Kidney Disease: Identification, Prevention, and Treatment 2022 , 149-169		
553	Differential and shared genetic effects on kidney function between diabetic and non-diabetic individuals. <i>Communications Biology</i> , 2022 , 5,	6.7	1
552	What Have We Learned so Far From the Use of Sodium-Glucose Cotransporter 2 Inhibitors in Clinical Practice?. <i>Advances in Chronic Kidney Disease</i> , 2021 , 28, 290-297	4.7	
551	The authors reply.. <i>Kidney International</i> , 2021 ,	9.9	
550	Effect of the Glucagon-like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: a Pooled Analysis of SUSTAIN 6 and LEADER Trials.. <i>Circulation</i> , 2021 ,	16.7	3

549	Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2021 ,	12.7	3
548	Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. <i>Lancet Diabetes and Endocrinology</i> , 2021 ,	18.1	3
547	Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial.. <i>Frontiers in Endocrinology</i> , 2021 , 12, 790405	5.7	3
546	Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post-hoc analyses from FIDELIO-DKD compared to reported CREDENCE results. <i>Nephrology Dialysis Transplantation</i> , 2021 ,	4.3	3
545	Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses from the FIGARO-DKD Trial. <i>Circulation</i> , 2021 ,	16.7	10
544	Linking Kidney and Cardiovascular Complications in Diabetes-Impact on Prognostication and Treatment: The 2019 Edwin Bierman Award Lecture. <i>Diabetes</i> , 2021 , 70, 39-50	0.9	5
543	Effect of empagliflozin on myocardial structure and function in patients with type 2 diabetes at high cardiovascular risk: the SIMPLE randomized clinical trial. <i>International Journal of Cardiovascular Imaging</i> , 2021 , 1	2.5	1
542	Cardiovascular autonomic neuropathy and the impact on progression of diabetic kidney disease in type 1 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2021 , 9,	4.5	3
541	Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. <i>Lancet Diabetes and Endocrinology</i> , 2021 , 9, 743-754	18.1	9
540	Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. <i>Lancet Diabetes and Endocrinology</i> , 2021 , 9, 755-766	18.1	10
539	Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.. <i>European Heart Journal</i> , 2021 ,	9.5	33
538	Effects of the chymase inhibitor fulacimstat in diabetic kidney disease-results from the CADA DIA trial. <i>Nephrology Dialysis Transplantation</i> , 2021 , 36, 2263-2273	4.3	5
537	Sex differences in the association between myocardial function and prognosis in type 1 diabetes without known heart disease: the Thousand & 1 Study. <i>European Heart Journal Cardiovascular Imaging</i> , 2021 , 22, 1017-1025	4.1	1
536	Irbesartan treatment does not influence plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3-deoxyglucosone in participants with type 2 diabetes and microalbuminuria: An IRMA2 sub-study. <i>Diabetic Medicine</i> , 2021 , 38, e14405	3.5	0
535	Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. <i>European Heart Journal</i> , 2021 , 42, 1216-1227	9.5	25
534	Prognostic and comparative performance of cardiovascular risk markers in patients with type 2 diabetes. <i>Journal of Diabetes</i> , 2021 , 13, 754-763	3.8	
533	Metformin and carotid intima-media thickness in never-smokers with type 1 diabetes: The REMOVAL trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1371-1378	6.7	3
532	A narrative review of new treatment options for chronic kidney disease in type 2 diabetes. <i>Annals of Translational Medicine</i> , 2021 , 9, 716	3.2	1

531	Data Sharing Under the General Data Protection Regulation: Time to Harmonize Law and Research Ethics?. <i>Hypertension</i> , 2021 , 77, 1029-1035	8.5	10
530	A New Panel-Estimated GFR, Including β Microglobulin and β Trace Protein and Not Including Race, Developed in a Diverse Population. <i>American Journal of Kidney Diseases</i> , 2021 , 77, 673-683.e1	7.4	16
529	The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes. <i>Scientific Reports</i> , 2021 , 11, 10624	4.9	3
528	Biomarkers for early detection of kidney disease: a call for pathophysiological relevance. <i>Kidney International</i> , 2021 , 99, 1240-1241	9.9	1
527	Response to Comment on Vistisen et al. A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. <i>Diabetes Care</i> 2021;44:901-907. <i>Diabetes Care</i> , 2021 , 44, e140-e141	14.6	1
526	Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial. <i>Diabetes Care</i> , 2021 , 44, 1894-1897	14.6	11
525	Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for diabetes after solid organ transplantation. <i>Transplant International</i> , 2021 , 34, 1341-1359	3	2
524	Replication and cross-validation of type 2 diabetes subtypes based on clinical variables: an IMI-RHAPSODY study. <i>Diabetologia</i> , 2021 , 64, 1982-1989	10.3	11
523	Endothelial glycocalyx and cardio-renal risk factors in type 1 diabetes. <i>PLoS ONE</i> , 2021 , 16, e0254859	3.7	1
522	Successful glucose lowering therapy triumphs in heart failure. <i>EClinicalMedicine</i> , 2021 , 37, 100996	11.3	1
521	Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 142-152	15.1	17
520	Circulating Free Fatty Acid and Phospholipid Signature Predicts Early Rapid Kidney Function Decline in Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2021 , 44, 2098-2106	14.6	6
519	Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: A randomised, double-blind, placebo-controlled crossover trial. <i>EClinicalMedicine</i> , 2021 , 37, 100895	11.3	9
518	Urinary peptidome and diabetic retinopathy in the DIRECT-Protect 1 and 2 trials. <i>Diabetic Medicine</i> , 2021 , 38, e14634	3.5	1
517	Genome-wide association study on coronary artery disease in type 1 diabetes suggests beta-defensin 127 as a risk locus. <i>Cardiovascular Research</i> , 2021 , 117, 600-612	9.9	2
516	Prognostic Value of Early Systolic Lengthening by Strain Imaging in Type 2 Diabetes. <i>Journal of the American Society of Echocardiography</i> , 2021 , 34, 127-135	5.8	2
515	A primer on metabolic memory: why existing diabetes treatments fail. <i>CKJ: Clinical Kidney Journal</i> , 2021 , 14, 756-767	4.5	0
514	Relationship between peripheral neuropathy, diastolic function and adverse cardiovascular outcome in individuals with type 1 diabetes mellitus without known cardiovascular disease: Results from the Thousand & 1 Study. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 158-165	6.7	0

513	Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. <i>Circulation</i> , 2021 , 143, 540-552	16.7	76
512	Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease. <i>Circulation</i> , 2021 , 143, 438-448	16.7	36
511	Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline. <i>Annals of Internal Medicine</i> , 2021 , 174, 385-394	8	25
510	SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. <i>American Journal of Kidney Diseases</i> , 2021 , 77, 94-109	7.4	27
509	Visit-to-visit variability of clinical risk markers in relation to long-term complications in type 1 diabetes. <i>Diabetic Medicine</i> , 2021 , 38, e14459	3.5	1
508	Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. <i>Lancet Diabetes and Endocrinology</i> , 2021 , 9, 22-31	18.1	91
507	Comparison of Natriuretic Peptides as Risk Markers for All-Cause Mortality and Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes. <i>Diabetes Care</i> , 2021 , 44, 595-603	14.6	1
506	SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. <i>Diabetes</i> , 2021 , 70, 1-16	0.9	18
505	Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline. <i>Kidney International</i> , 2021 , 99, 926-939	9.9	6
504	Serum glycated albumin predicts all-cause mortality in dialysis patients with diabetes mellitus: meta-analysis and systematic review of a predictive biomarker. <i>Acta Diabetologica</i> , 2021 , 58, 81-91	3.9	14
503	Major adverse renal events (MARE): a proposal to unify renal endpoints. <i>Nephrology Dialysis Transplantation</i> , 2021 , 36, 491-497	4.3	9
502	Non-invasive assessment of temporal changes in myocardial microvascular function in persons with type 2 diabetes and healthy controls. <i>Diabetic Medicine</i> , 2021 , 38, e14517	3.5	2
501	Genome-wide association study of circulating interleukin 6 levels identifies novel loci. <i>Human Molecular Genetics</i> , 2021 , 30, 393-409	5.6	6
500	Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial. <i>Diabetes Care</i> , 2021 , 44, 1020-1026	14.6	7
499	Plasma trimethylamine N-oxide and its metabolic precursors and risk of mortality, cardiovascular and renal disease in individuals with type 2-diabetes and albuminuria. <i>PLoS ONE</i> , 2021 , 16, e0244402	3.7	8
498	Effect of Liraglutide on Arterial Inflammation Assessed as [F]FDG Uptake in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Circulation: Cardiovascular Imaging</i> , 2021 , 14, e012174	3.9	8
497	The Low-Expression Variant of Is Associated With Cardiovascular Disease in Type 1 Diabetes. <i>Diabetes</i> , 2021 , 70, 2391-2401	0.9	0
496	Association of Coding Variants in Hydroxysteroid 17-beta Dehydrogenase 14 () with Reduced Progression to End Stage Kidney Disease in Type 1 Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2021 , 32, 2634-2651	12.7	2

495	Sodium-glucose cotransporter 2 inhibitors for diabetes mellitus control after kidney transplantation: Review of the current evidence. <i>Nephrology</i> , 2021 , 26, 1007-1017	2.2	2
494	Faecal biomarkers in type 1 diabetes with and without diabetic nephropathy. <i>Scientific Reports</i> , 2021 , 11, 15208	4.9	0
493	A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. <i>Kidney International</i> , 2021 , 100, 215-224	9.9	35
492	Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2021 , 32, 2352-2361	12.7	13
491	Effect of Liraglutide on Vascular Inflammation Evaluated by [Cu]DOTATATE. <i>Diagnostics</i> , 2021 , 11,	3.8	2
490	Medical therapies for prevention of cardiovascular and renal events in patients with atrial fibrillation and diabetes mellitus. <i>Europace</i> , 2021 , 23, 1873-1891	3.9	2
489	Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2021 , 385, 2252-2263	59.2	103
488	Distinct Molecular Signatures of Clinical Clusters in People With Type 2 Diabetes: An IMI-RHAPSODY Study. <i>Diabetes</i> , 2021 , 70, 2683-2693	0.9	4
487	Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE Trial. <i>Journal of the American Heart Association</i> , 2021 , 10, e020418	6	3
486	Liraglutide reduces cardiac adipose tissue in type 2 diabetes: A secondary analysis of the LIRAFLAME randomized placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 2651-2659	6.7	1
485	Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure. <i>JACC: Heart Failure</i> , 2021 , 9, 807-820	7.9	11
484	Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial. <i>BMJ Open Diabetes Research and Care</i> , 2021 , 9,	4.5	3
483	New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. <i>New England Journal of Medicine</i> , 2021 , 385, 1737-1749	59.2	125
482	Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2021 , 32, 2900-2911	12.7	1
481	A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. <i>Kidney International</i> , 2021 ,	9.9	9
480	Effect of liraglutide on expression of inflammatory genes in type 2 diabetes. <i>Scientific Reports</i> , 2021 , 11, 18522	4.9	1
479	A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. <i>Diabetes Care</i> , 2021 , 44, 901-907	14.6	5
478	Microalbuminuria constitutes a Clinical Action Item for Clinicians in 2021.. <i>American Journal of Medicine</i> , 2021 ,	2.4	1

477	The Association Between Cardiovascular Autonomic Function and Changes in Kidney and Myocardial Function in Type 2 Diabetes and Healthy Controls.. <i>Frontiers in Endocrinology</i> , 2021 , 12, 780679	5.7	0
476	Mendelian randomization analysis does not support causal associations of birth weight with hypertension risk and blood pressure in adulthood. <i>European Journal of Epidemiology</i> , 2020 , 35, 685-697	12.1	2
475	Omics research in diabetic kidney disease: new biomarker dimensions and new understandings?. <i>Journal of Nephrology</i> , 2020 , 33, 931-948	4.8	4
474	Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2020 , 382, 2493-2503	59.2	100
473	Epicardial adipose tissue: an emerging biomarker of cardiovascular complications in type 2 diabetes?. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2020 , 11, 2042018820928824	4.5	15
472	Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment. <i>Kidney International</i> , 2020 , 98, 839-848	9.9	65
471	Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 2077-2088	6.7	3
470	Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35, 274-282	4.3	105
469	Post-Systolic Shortening by Speckle Tracking Echocardiography Predicts Cardiac Events in Type 2 Diabetes. <i>JACC: Cardiovascular Imaging</i> , 2020 , 13, 1289-1291	8.4	4
468	Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 301-312	18.1	75
467	Relation of cardiac adipose tissue to coronary calcification and myocardial microvascular function in type 1 and type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2020 , 19, 16	8.7	10
466	Describing the fecal metabolome in cryogenically collected samples from healthy participants. <i>Scientific Reports</i> , 2020 , 10, 885	4.9	8
465	Effect of dapagliflozin on cardiac function in people with type 2 diabetes and albuminuria - A double blind randomized placebo-controlled crossover trial. <i>Journal of Diabetes and Its Complications</i> , 2020 , 34, 107590	3.2	6
464	Hyperoxia improves autonomic function in individuals with long-duration type 1 diabetes and macroalbuminuria. <i>Diabetic Medicine</i> , 2020 , 37, 1561-1568	3.5	1
463	Lipoprotein(a)and renal function decline, cardiovascular disease and mortality in type 2 diabetes and microalbuminuria. <i>Journal of Diabetes and Its Complications</i> , 2020 , 34, 107593	3.2	2
462	Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions. <i>PLoS ONE</i> , 2020 , 15, e0243737	3.7	7
461	Cardiovascular prognostic value of echocardiography and N terminal pro B-type natriuretic peptide in type 1 diabetes: the Thousand & 1 Study. <i>European Journal of Endocrinology</i> , 2020 , 182, 481-488	6.5	1
460	Metabolomic and Proteomic Techniques for Establishing Biomarkers and Improving Our Understanding of Pathophysiology in Diabetic Nephropathy. <i>Methods in Molecular Biology</i> , 2020 , 2067, 287-306	1.4	2

459	490-P: Renal Effects of Metformin in Type 1 Diabetes (T1D): The REMOVAL Trial. <i>Diabetes</i> , 2020 , 69, 490-499		
458	28-LB: Improved Time in Glucose Range over One Year Is Associated with Reduced Albuminuria in Sensor-Augmented Insulin Pump-Treated Type 1 Diabetes. <i>Diabetes</i> , 2020 , 69, 28-LB	0.9	1
457	1532-P: Investigating Biomarkers of the Immune Response and Tissue Remodeling in Patients with Type 2 Diabetes with Microalbuminuria. <i>Diabetes</i> , 2020 , 69, 1532-P	0.9	
456	Copeptin and renal function decline, cardiovascular events and mortality in type 1 diabetes. <i>Nephrology Dialysis Transplantation</i> , 2020 ,	4.3	2
455	Concomitant diabetes with atrial fibrillation and anticoagulation management considerations. <i>European Heart Journal Supplements</i> , 2020 , 22, O78-O86	1.5	5
454	Uncarboxylated matrix Gla-protein: A biomarker of vitamin K status and cardiovascular risk. <i>Clinical Biochemistry</i> , 2020 , 83, 49-56	3.5	14
453	Performance of Indexed and Nonindexed Estimated GFR. <i>American Journal of Kidney Diseases</i> , 2020 , 76, 446-449	7.4	5
452	Changes in diabetes distress among people with type 2 diabetes during a risk screening programme for diabetic kidney disease - Longitudinal observations of the PRIORITY study. <i>Journal of Diabetes and Its Complications</i> , 2020 , 34, 107467	3.2	2
451	2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i> , 2020 , 63, 221-228	10.3	235
450	2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> , 2020 , 43, 487-493	14.6	483
449	Mitigating risk of aldosterone in diabetic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2020 , 29, 145-151	3.5	12
448	KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. <i>Kidney International</i> , 2020 , 98, S1-S115	9.9	251
447	MR-proANP and incident cardiovascular disease in patients with type 2 diabetes with and without heart failure with preserved ejection fraction. <i>Cardiovascular Diabetology</i> , 2020 , 19, 180	8.7	2
446	Dapagliflozin in Patients with Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2020 , 383, 1436-1446	14.6	865
445	Metformin and cardiorenal outcomes in diabetes: A reappraisal. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 904-915	6.7	26
444	Association between severe diabetic retinopathy and lectin pathway proteins - an 18-year follow-up study with newly diagnosed type 1 diabetes patients. <i>Immunobiology</i> , 2020 , 225, 151939	3.4	0
443	Liver nucleotide biosynthesis is linked to protection from vascular complications in individuals with long-term type 1 diabetes. <i>Scientific Reports</i> , 2020 , 10, 11561	4.9	2
442	Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. <i>Nephrology Dialysis Transplantation</i> , 2020 ,	4.3	20

441	Carotid-Femoral Pulse Wave Velocity as a Risk Marker for Development of Complications in Type 1 Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2020 , 9, e017165	6	6
440	Circulating Metabolites and Lipids Are Associated to Diabetic Retinopathy in Individuals With Type 1 Diabetes. <i>Diabetes</i> , 2020 , 69, 2217-2226	0.9	12
439	Diabetes mellitus in chronic kidney disease: Biomarkers beyond HbA1c to estimate glycemic control and diabetes-dependent morbidity and mortality. <i>Journal of Diabetes and Its Complications</i> , 2020 , 34, 107707	3.2	7
438	A Targeted Multiomics Approach to Identify Biomarkers Associated with Rapid eGFR Decline in Type 1 Diabetes. <i>American Journal of Nephrology</i> , 2020 , 51, 839-848	4.6	3
437	Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2020 , 383, 2219-2229	59.2	347
436	The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35, 1700-1711	4.3	52
435	Gut microbiota profile and selected plasma metabolites in type 1 diabetes without and with stratification by albuminuria. <i>Diabetologia</i> , 2020 , 63, 2713-2724	10.3	8
434	Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 880-893	18.1	27
433	Improved Time in Range Over 1 Year Is Associated With Reduced Albuminuria in Individuals With Sensor-Augmented Insulin Pump-Treated Type 1 Diabetes. <i>Diabetes Care</i> , 2020 , 43, 2882-2885	14.6	26
432	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2020 , 41, 255-323	9.5	1360
431	Plasma Metabolomics Identifies Markers of Impaired Renal Function: A Meta-analysis of 3089 Persons with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	11
430	Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions 2020 , 15, e0243737		
429	Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions 2020 , 15, e0243737		
428	Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions 2020 , 15, e0243737		
427	Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions 2020 , 15, e0243737		
426	Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions 2020 , 15, e0243737		
425	Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions 2020 , 15, e0243737		
424	Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions 2020 , 15, e0243737		

423	Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions 2020 , 15, e0243737		
422	Epicardial adipose tissue predicts incident cardiovascular disease and mortality in patients with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2019 , 18, 114	8.7	30
421	Association of Birth Weight With Type 2 Diabetes and Glycemic Traits: A Mendelian Randomization Study. <i>JAMA Network Open</i> , 2019 , 2, e1910915	10.4	14
420	Targeted Clinical Metabolite Profiling Platform for the Stratification of Diabetic Patients. <i>Metabolites</i> , 2019 , 9,	5.6	10
419	Genome-Wide Association Study of Apparent Treatment-Resistant Hypertension in the CHARGE Consortium: The CHARGE Pharmacogenetics Working Group. <i>American Journal of Hypertension</i> , 2019 , 32, 1146-1153	2.3	2
418	Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1261-1265	6.7	7
417	Utility of Plasma Concentration of Trimethylamine N-Oxide in Predicting Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes. <i>Diabetes Care</i> , 2019 , 42, 1512-1520	14.6	41
416	Efficacy of Long-Term Remote Ischemic Conditioning on Vascular and Neuronal Function in Type 2 Diabetes Patients With Peripheral Arterial Disease. <i>Journal of the American Heart Association</i> , 2019 , 8, e011779	6	9
415	Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 515-527	18.1	99
414	A catalog of genetic loci associated with kidney function from analyses of a million individuals. <i>Nature Genetics</i> , 2019 , 51, 957-972	36.3	217
413	Beneficial impact of intensified multifactorial intervention on risk of stroke: outcome of 21 years of follow-up in the randomised Steno-2 Study. <i>Diabetologia</i> , 2019 , 62, 1575-1580	10.3	11
412	Effects of Dapagliflozin on Volume Status When Added to Renin-Angiotensin System Inhibitors. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	37
411	Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol-Rationale, Design, and Baseline Data. <i>Diabetes Care</i> , 2019 , 42, 1454-1463	14.6	28
410	Epicardial and pericardial adipose tissues are associated with reduced diastolic and systolic function in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 2006-2011	6.7	20
409	Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease. <i>Kidney International</i> , 2019 , 96, 1030-1036	9.9	15
408	An echocardiographic substrate for dyspnea identifies high risk patients with type 2 diabetes. <i>International Journal of Cardiology</i> , 2019 , 289, 119-124	3.2	2
407	Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 429-441	18.1	81
406	Prognostic value of ratio of transmitral early filling velocity to early diastolic strain rate in patients with Type 2 diabetes. <i>European Heart Journal Cardiovascular Imaging</i> , 2019 , 20, 1171-1178	4.1	5

405	Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2019 , 42, 1112-1119	14.6	19
404	Uric Acid Is an Independent Risk Factor for Decline in Kidney Function, Cardiovascular Events, and Mortality in Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2019 , 42, 1088-1094	14.6	33
403	Improvements in albuminuria and chronic kidney disease progression with the appetite suppressant lorcaserin. <i>Kidney International</i> , 2019 , 95, 1287-1288	9.9	0
402	A marker of type VI collagen formation (PRO-C6) is associated with higher arterial stiffness in type 1 diabetes. <i>Acta Diabetologica</i> , 2019 , 56, 711-712	3.9	3
401	Cardiac Autonomic Function Is Associated With Myocardial Flow Reserve in Type 1 Diabetes. <i>Diabetes</i> , 2019 , 68, 1277-1286	0.9	7
400	Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2019 , 393, 1937-1947	4.0	209
399	Cardiac ventricular sizes are reduced in patients with long-term, normoalbuminuric type 1 diabetes compared to the non-diabetic background population. <i>Diabetes and Vascular Disease Research</i> , 2019 , 16, 289-296	3.3	1
398	Sa0010EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES IN A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS. <i>Nephrology Dialysis Transplantation</i> , 2019 , 34,	4.3	1
397	FP483EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) IN A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER. <i>Nephrology Dialysis Transplantation</i> , 2019 , 34,	4.3	1
396	Markers of Collagen Formation and Degradation Reflect Renal Function and Predict Adverse Outcomes in Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2019 , 42, 1760-1768	14.6	15
395	Progressive Decline in Estimated Glomerular Filtration Rate in Patients With Diabetes After Moderate Loss in Kidney Function-Even Without Albuminuria. <i>Diabetes Care</i> , 2019 , 42, 1886-1894	14.6	51
394	The effect of needle tenotomy on hammer, mallet and claw toe deformities in patients with diabetes, a retrospective study. <i>Journal of Clinical and Translational Endocrinology</i> , 2019 , 18, 100208	2.4	2
393	Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved in Glomerular Basement Membrane Collagen. <i>Journal of the American Society of Nephrology: JASN</i> , 2019 , 30, 2000-2016	12.7	66
392	Echocardiography improves prediction of major adverse cardiovascular events in a population with type 1 diabetes and without known heart disease: the Thousand & 1 Study. <i>Diabetologia</i> , 2019 , 62, 2354-2364	19.2	9
391	Lipidomic analysis reveals sphingomyelin and phosphatidylcholine species associated with renal impairment and all-cause mortality in type 1 diabetes. <i>Scientific Reports</i> , 2019 , 9, 16398	4.9	24
390	Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial). <i>BMJ Open</i> , 2019 , 9, e029098	3	3
389	Linking glycemic dysregulation in diabetes to symptoms, comorbidities, and genetics through EHR data mining. <i>ELife</i> , 2019 , 8,	8.9	5
388	237-OR: Beneficial Impact of Intensified Multifactorial Intervention on Stroke in the Steno-2 Study. <i>Diabetes</i> , 2019 , 68, 237-OR	0.9	

387	456-P: The REMOVAL Trial: Effect of Metformin on Markers of Cardiometabolic Risk in Patients with Type 1 Diabetes. <i>Diabetes</i> , 2019 , 68, 456-P	0.9	
386	526-P: Dapagliflozin Improves the Urinary CKD273 Proteomic Score When Added to Renin-Angiotensin Blockade in Patients with Type 2 Diabetes and Nephropathy. <i>Diabetes</i> , 2019 , 68, 526-P ⁹	0.9	
385	40-LB: Association between Complement and Severe Retinal Complications in Type 1 Diabetes: An 18-Year Follow-Up Study. <i>Diabetes</i> , 2019 , 68, 40-LB	0.9	1
384	Left ventricular remodelling and cardiac chamber sizes in long-term, normoalbuminuric type 1 diabetes patients with and without cardiovascular autonomic neuropathy. <i>Journal of Diabetes and Its Complications</i> , 2019 , 33, 171-177	3.2	2
383	Response to Comment on Pilemann-Lyberg et al. Uric Acid Is an Independent Risk Factor for Decline in Kidney Function, Cardiovascular Events, and Mortality in Patients With Type 1 Diabetes. <i>Diabetes Care</i> 2019;42:1088-1094. <i>Diabetes Care</i> , 2019 , 42, e188	14.6	1
382	OBESITY REMAINS A MAJOR RISK FACTOR ASSOCIATED WITH VASCULAR STIFFENING IN TYPE 2 DIABETES. <i>Journal of Hypertension</i> , 2019 , 37, e65	1.9	
381	Metabolomic Assessment Reveals Alteration in Polyols and Branched Chain Amino Acids Associated With Present and Future Renal Impairment in a Discovery Cohort of 637 Persons With Type 1 Diabetes. <i>Frontiers in Endocrinology</i> , 2019 , 10, 818	5.7	19
380	A novel rare CUBN variant and three additional genes identified in Europeans with and without diabetes: results from an exome-wide association study of albuminuria. <i>Diabetologia</i> , 2019 , 62, 292-305	10.3	17
379	Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 720-725	6.7	10
378	Prevalence of heart failure and the diagnostic value of MR-proANP in outpatients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 736-740	6.7	9
377	Clinical Features and Natural Course of Diabetic Nephropathy 2019 , 21-32		3
376	Predictive value of echocardiography in Type 2 diabetes. <i>European Heart Journal Cardiovascular Imaging</i> , 2019 , 20, 687-693	4.1	16
375	Variations in Risk of End-Stage Renal Disease and Risk of Mortality in an International Study of Patients With Type 1 Diabetes and Advanced Nephropathy. <i>Diabetes Care</i> , 2019 , 42, 93-101	14.6	24
374	Urinary Proteomics and Precision Medicine for Chronic Kidney Disease: Current Status and Future Perspectives. <i>Proteomics - Clinical Applications</i> , 2019 , 13, e1800176	3.1	13
373	Myocardial flow reserve assessed by cardiac 82Rb positron emission tomography/computed tomography is associated with albumin excretion in patients with Type 1 diabetes. <i>European Heart Journal Cardiovascular Imaging</i> , 2019 , 20, 796-803	4.1	8
372	Generalised arterial calcification in normoalbuminuric patients with type 1 diabetes with and without cardiovascular autonomic neuropathy. <i>Diabetes and Vascular Disease Research</i> , 2019 , 16, 98-102 ^{3.3}	3.3	11
371	Guidelines and clinical practice at the primary level of healthcare in patients with type 2 diabetes mellitus with and without kidney disease in five European countries. <i>Diabetes and Vascular Disease Research</i> , 2019 , 16, 47-56	3.3	9
370	Uric acid is not associated with diabetic nephropathy and other complications in type 1 diabetes. <i>Nephrology Dialysis Transplantation</i> , 2019 , 34, 659-666	4.3	7

369	Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial) 2019 , 9, e029098		2
368	Predicting albuminuria response to spironolactone treatment with urinary proteomics in patients with type 2 diabetes and hypertension. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, 296-303	4.3	22
367	A Prospective Cohort Study in Patients with Type 2 Diabetes Mellitus for Validation of Biomarkers (PROVALID) - Study Design and Baseline Characteristics. <i>Kidney and Blood Pressure Research</i> , 2018 , 43, 181-190	3.1	14
366	Serum uric acid and progression of diabetic nephropathy in type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2018 , 32, 470-473	3.2	6
365	Higher Collagen VI Formation Is Associated With All-Cause Mortality in Patients With Type 2 Diabetes and Microalbuminuria. <i>Diabetes Care</i> , 2018 , 41, 1493-1500	14.6	30
364	Associations between advanced glycation endproducts and matrix metalloproteinases and its inhibitor in individuals with type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2018 , 32, 325-329	3.2	9
363	Diagnosis of diabetic kidney disease: state of the art and future perspective. <i>Kidney International Supplements</i> , 2018 , 8, 2-7	6.3	117
362	The effect of uric acid lowering treatment on albuminuria and renal function in Type 1 diabetes: a randomized clinical trial. <i>Diabetic Medicine</i> , 2018 , 35, 392-393	3.5	3
361	Urinary proteomics for prediction of mortality in patients with type 2 diabetes and microalbuminuria. <i>Cardiovascular Diabetology</i> , 2018 , 17, 50	8.7	21
360	Subclassification of diabetes based on quantitative traits. <i>Nature Reviews Nephrology</i> , 2018 , 14, 355-356	14.9	2
359	A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes. <i>Diabetes</i> , 2018 , 67, 1414-1427	0.9	71
358	Prognosis and treatment of diabetic nephropathy: Recent advances and perspectives. <i>Nephrologie Et Therapeutique</i> , 2018 , 14 Suppl 1, S31-S37	0.6	24
357	Arterial-ventricular coupling in type 1 diabetes: arterial stiffness is associated with impaired global longitudinal strain in type 1 diabetes patients-the Thousand & 1 Study. <i>Acta Diabetologica</i> , 2018 , 55, 21-29	3.9	4
356	Presence of micro- and macroalbuminuria and the association with cardiac mechanics in patients with type 2 diabetes. <i>European Heart Journal Cardiovascular Imaging</i> , 2018 , 19, 1034-1041	4.1	16
355	Type 1 diabetes is associated with T-wave morphology changes. The Thousand & 1 Study. <i>Journal of Electrocardiology</i> , 2018 , 51, S72-S77	1.4	3
354	Growth differentiation factor-15 and fibroblast growth factor-23 are associated with mortality in type 2 diabetes - An observational follow-up study. <i>PLoS ONE</i> , 2018 , 13, e0196634	3.7	23
353	Cardiovascular autonomic neuropathy and bone metabolism in Type 1 diabetes. <i>Diabetic Medicine</i> , 2018 , 35, 1596-1604	3.5	8
352	Novel risk genes identified in a genome-wide association study for coronary artery disease in patients with type 1 diabetes. <i>Cardiovascular Diabetology</i> , 2018 , 17, 61	8.7	17

351	Urinary tubular biomarkers as predictors of kidney function decline, cardiovascular events and mortality in microalbuminuric type 2 diabetic patients. <i>Acta Diabetologica</i> , 2018 , 55, 1143-1150	3.9	15
350	Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study. <i>Diabetologia</i> , 2018 , 61, 1724-1733	10.3	47
349	How Does Risk Screening for Kidney Disease Influence Diabetes Distress?. <i>Diabetes</i> , 2018 , 67, 819-P	0.9	
348	Biomarkers of inflammation and endothelial dysfunction as predictors of pulse pressure and incident hypertension in type 1 diabetes: a 20 year life-course study in an inception cohort. <i>Diabetologia</i> , 2018 , 61, 231-241	10.3	14
347	SP417EFFECT OF DAPAGLIFLOZIN ON ALBUMINURIA AND THE RENIN-ANGIOTENSIN SYSTEM WHEN ADDED TO RENIN-ANGIOTENSIN BLOCKADE IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, i488-i488	4.3	
346	SP420ALTERED LEVELS OF PLASMA LIPIDS ARE ASSOCIATED WITH DIABETIC KIDNEY DISEASE: A CROSS-SECTIONAL STUDY OF PLASMA LIPIDOMICS IN TYPE 1 DIABETES. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, i489-i489	4.3	
345	A3993 Myocardial flow reserve assessed by Cardiac 82Rb PET/CT is associated with albumin excretion in patients with type 1 diabetes. <i>Journal of Hypertension</i> , 2018 , 36, e147	1.9	
344	SEX-SPECIFIC REGULATION OF URINARY PEPTIDES IN EARLY DIABETIC NEPHROPHY. <i>Journal of Hypertension</i> , 2018 , 36, e240	1.9	
343	Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial. <i>Lancet Diabetes and Endocrinology</i> , 2018 , 6, 925-933	18.1	20
342	Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i> , 2018 , 61, 2461-2498	10.3	656
341	Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> , 2018 , 41, 2669-2701	14.6	1307
340	Application of urinary proteomics as possible risk predictor of renal and cardiovascular complications in patients with type 2-diabetes and microalbuminuria. <i>Journal of Diabetes and Its Complications</i> , 2018 , 32, 1133-1140	3.2	4
339	Burden of Uncontrolled Metabolic Risk Factors and Left Ventricular Structure and Function in Patients With Type 2 Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2018 , 7, e008856	6	11
338	Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease. <i>Journal of Diabetes and Its Complications</i> , 2018 , 32, 1113-1117	3.2	9
337	LeucoPatch system for the management of hard-to-heal diabetic foot ulcers in the UK, Denmark, and Sweden: an observer-masked, randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2018 , 6, 870-878	18.1	48
336	Cardiac repolarization and depolarization in people with Type 1 diabetes with normal ejection fraction and without known heart disease: a case-control study. <i>Diabetic Medicine</i> , 2018 , 35, 1337-1344	3.5	10
335	Characteristics of high- and low-risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes. <i>Diabetic Medicine</i> , 2018 , 35, 1375-1382	3.5	19
334	Stratification of type 2 diabetes based on routine clinical markers. <i>Diabetes Research and Clinical Practice</i> , 2018 , 141, 275-283	7.4	22

333	Three-phase bone scintigraphy for diagnosis of Charcot neuropathic osteoarthropathy in the diabetic foot - does quantitative data improve diagnostic value?. <i>Clinical Physiology and Functional Imaging</i> , 2017 , 37, 30-36	2.4	4
332	Higher Parathyroid Hormone Level Is Associated With Increased Arterial Stiffness in Type 1 Diabetes. <i>Diabetes Care</i> , 2017 , 40, e32-e33	14.6	2
331	Systems Biology-Derived Biomarkers to Predict Progression of Renal Function Decline in Type 2 Diabetes. <i>Diabetes Care</i> , 2017 , 40, 391-397	14.6	33
330	Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 901-905	6.7	31
329	Effect of Pancreatic Hormones on pro-Atrial Natriuretic Peptide in Humans. <i>EBioMedicine</i> , 2017 , 17, 88-94	1.8	7
328	Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits. <i>Kidney International</i> , 2017 , 91, 982-988	9.9	51
327	Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study. <i>Cardiovascular Diabetology</i> , 2017 , 16, 55	8.7	35
326	Higher Plasma Methylglyoxal Levels Are Associated With Incident Cardiovascular Disease in Individuals With Type 1 Diabetes: A 12-Year Follow-up Study. <i>Diabetes</i> , 2017 , 66, 2278-2283	0.9	45
325	Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 597-609	18.1	177
324	Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes. <i>Kidney International</i> , 2017 , 91, 1300-1311	9.9	116
323	Effect of large weight reductions on measured and estimated kidney function. <i>BMC Nephrology</i> , 2017 , 18, 52	2.7	23
322	Incident microalbuminuria and complement factor mannan-binding lectin-associated protein 19 in people with newly diagnosed type 1 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2017 , 33, e2895	7.5	3
321	Variability in response to albuminuria-lowering drugs: true or random?. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 1197-1204	3.8	14
320	Metformin in adults with type 1 diabetes: Design and methods of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): An international multicentre trial. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 509-516	6.7	24
319	Pooled Analysis of Multiple Crossover Trials To Optimize Individual Therapy Response to Renin-Angiotensin-Aldosterone System Intervention. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017 , 12, 1804-1813	6.9	7
318	Trimethylamine N-oxide (TMAO) as a New Potential Therapeutic Target for Insulin Resistance and Cancer. <i>Current Pharmaceutical Design</i> , 2017 , 23, 3699-3712	3.3	64
317	Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria. <i>Cardiovascular Diabetology</i> , 2017 , 16, 88	8.7	27
316	Circulating matrix metalloproteinases are associated with arterial stiffness in patients with type 1 diabetes: pooled analysis of three cohort studies. <i>Cardiovascular Diabetology</i> , 2017 , 16, 139	8.7	16

315	Diabetes and Hypertension: A Position Statement by the American Diabetes Association. <i>Diabetes Care</i> , 2017 , 40, 1273-1284	14.6	312
314	Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials. <i>Journal of Diabetes and Its Complications</i> , 2017 , 31, 1164-1168	3.2	4
313	Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy. <i>Kidney International</i> , 2017 , 92, 1242-1248	9.9	17
312	Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker. <i>Kidney International Reports</i> , 2017 , 2, 1066-1075	4.1	55
311	[OP.4B.04] URINARY PROTEOMICS PREDICTS MORTALITY IN TYPE 2 DIABETES PATIENTS WITH MICROALBUMINURIA. <i>Journal of Hypertension</i> , 2017 , 35, e38-e39	1.9	
310	Toe-brachial index as a predictor of cardiovascular disease and all-cause mortality in people with type 2 diabetes and microalbuminuria. <i>Diabetologia</i> , 2017 , 60, 1883-1891	10.3	14
309	Epicardial, pericardial and total cardiac fat and cardiovascular disease in type 2 diabetic patients with elevated urinary albumin excretion rate. <i>European Journal of Preventive Cardiology</i> , 2017 , 24, 1517-1524	3.9	24
308	The effect of liraglutide on renal function: A randomized clinical trial. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 239-247	6.7	55
307	Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatment. <i>Journal of Diabetes and Its Complications</i> , 2017 , 31, 162-168	3.2	10
306	The Genetic Landscape of Renal Complications in Type 1 Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2017 , 28, 557-574	12.7	69
305	A urinary proteome-based classifier for the early detection of decline in glomerular filtration. <i>Nephrology Dialysis Transplantation</i> , 2017 , 32, 1510-1516	4.3	60
304	Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study. <i>Nephrology Dialysis Transplantation</i> , 2017 , 32, 1866-1873	4.3	47
303	Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis. <i>Nephrology Dialysis Transplantation</i> , 2017 , 32, 2079-2089	4.3	44
302	Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia--the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT). <i>Journal of Human Hypertension</i> , 2016 , 30, 46-52	2.6	9
301	Angiogenic microRNAs Linked to Incidence and Progression of Diabetic Retinopathy in Type 1 Diabetes. <i>Diabetes</i> , 2016 , 65, 216-27	0.9	81
300	Glucose-Dependent Insulinotropic Polypeptide Stimulates Osteopontin Expression in the Vasculature via Endothelin-1 and CREB. <i>Diabetes</i> , 2016 , 65, 239-54	0.9	31
299	Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. <i>Diabetologia</i> , 2016 , 59, 2298-2307	10.3	268
298	Renin angiotensin system blockade reduces urinary levels of soluble urokinase plasminogen activator receptor (suPAR) in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2016 , 30, 1440-1442	3.2	7

297	Methylglyoxal is associated with changes in kidney function among individuals with screen-detected Type 2 diabetes mellitus. <i>Diabetic Medicine</i> , 2016 , 33, 1625-1631	3.5	29
296	Impact of type 2 diabetes and duration of type 2 diabetes on cardiac structure and function. <i>International Journal of Cardiology</i> , 2016 , 221, 114-21	3.2	24
295	High osteoprotegerin is associated with development of foot ulcer in type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2016 , 30, 1603-1608	3.2	5
294	suPAR level is associated with myocardial impairment assessed with advanced echocardiography in patients with type 1 diabetes with normal ejection fraction and without known heart disease or end-stage renal disease. <i>European Journal of Endocrinology</i> , 2016 , 174, 745-53	6.5	16
293	Retinopathy is associated with impaired myocardial function assessed by advanced echocardiography in type 1 diabetes patients - The Thousand & 1 Study. <i>Diabetes Research and Clinical Practice</i> , 2016 , 116, 263-9	7.4	7
292	Early myocardial impairment in type 1 diabetes patients without known heart disease assessed with tissue Doppler echocardiography: The Thousand & 1 study. <i>Diabetes and Vascular Disease Research</i> , 2016 , 13, 260-7	3.3	11
291	Abnormal echocardiography in patients with type 2 diabetes and relation to symptoms and clinical characteristics. <i>Diabetes and Vascular Disease Research</i> , 2016 , 13, 321-30	3.3	28
290	Impaired coronary microcirculation in type 2 diabetic patients is associated with elevated circulating regulatory T cells and reduced number of IL-21R+ T cells. <i>Cardiovascular Diabetology</i> , 2016 , 15, 67	8.7	7
289	Markers of inflammation and endothelial dysfunction are associated with incident cardiovascular disease, all-cause mortality, and progression of coronary calcification in type 2 diabetic patients with microalbuminuria. <i>Journal of Diabetes and Its Complications</i> , 2016 , 30, 248-55	3.2	39
288	Cardiac (82)Rb PET/CT for fast and non-invasive assessment of microvascular function and structure in asymptomatic patients with type 2 diabetes. <i>Diabetologia</i> , 2016 , 59, 371-8	10.3	45
287	Cardiac time intervals and the association with 2D-speckle-tracking, tissue Doppler and conventional echocardiography: the Thousand&1 Study. <i>International Journal of Cardiovascular Imaging</i> , 2016 , 32, 789-98	2.5	4
286	Self-reported dyspnea is associated with impaired global longitudinal strain in ambulatory type 1 diabetes patients with normal ejection fraction and without known heart disease - The Thousand & 1 Study. <i>Journal of Diabetes and Its Complications</i> , 2016 , 30, 928-34	3.2	6
285	Statins are independently associated with increased HbA1c in type 1 diabetes--The Thousand & 1 Study. <i>Diabetes Research and Clinical Practice</i> , 2016 , 111, 51-7	7.4	8
284	Are human endogenous retroviruses triggers of autoimmune diseases? Unveiling associations of three diseases and viral loci. <i>Immunologic Research</i> , 2016 , 64, 55-63	4.3	29
283	Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial. <i>Diabetes Care</i> , 2016 , 39, 222-30	14.6	109
282	The Danish Adult Diabetes Registry. <i>Clinical Epidemiology</i> , 2016 , 8, 429-434	5.9	46
281	Cardiac Autonomic Function Is Associated With the Coronary Microcirculatory Function in Patients With Type 2 Diabetes. <i>Diabetes</i> , 2016 , 65, 3129-38	0.9	16
280	Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus. <i>Journal of Translational Medicine</i> , 2016 , 14, 203	8.5	13

279	Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephropathy in Type 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial. <i>BMJ Open</i> , 2016 , 6, e010310	3	92
278	Urinary biomarkers are associated with incident cardiovascular disease, all-cause mortality and deterioration of kidney function in type 2 diabetic patients with microalbuminuria. <i>Diabetologia</i> , 2016 , 59, 1549-1557	10.3	17
277	Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: A systematic review. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2016 , 17,	3	33
276	Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. <i>BMC Nephrology</i> , 2016 , 17, 127	2.7	83
275	Global Changes in Food Supply and the Obesity Epidemic. <i>Current Obesity Reports</i> , 2016 , 5, 449-455	8.4	98
274	Cholesterol remnants and triglycerides are associated with decreased myocardial function in patients with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2016 , 15, 137	8.7	14
273	Several Conventional Risk Markers Suggesting Presence of Albuminuria Are Weak Among Rural Africans With Hypertension. <i>Journal of Clinical Hypertension</i> , 2016 , 18, 27-30	2.3	5
272	Improved prognosis of diabetic nephropathy in type 1 diabetes. <i>Kidney International</i> , 2015 , 87, 417-26	9.9	45
271	Diagnosis and treatment of early renal disease in patients with type 2 diabetes mellitus: what are the clinical needs?. <i>Nephrology Dialysis Transplantation</i> , 2015 , 30 Suppl 4, iv1-5	4.3	8
270	Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes. <i>Nephrology Dialysis Transplantation</i> , 2015 , 30 Suppl 4, iv86-95	4.3	29
269	Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2015 , 29, 670-4	3.2	47
268	Global longitudinal strain is not impaired in type 1 diabetes patients without albuminuria: the Thousand & 1 study. <i>JACC: Cardiovascular Imaging</i> , 2015 , 8, 400-410	8.4	67
267	Effects of 12 weeks of treatment with fermented milk on blood pressure, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind placebo-controlled study. <i>European Journal of Endocrinology</i> , 2015 , 172, 11-20	6.5	49
266	Increased plasma concentrations of midregional proatrial natriuretic Peptide is associated with risk of cardiorenal dysfunction in type 1 diabetes. <i>American Journal of Hypertension</i> , 2015 , 28, 772-9	2.3	8
265	Genetic risk factors affecting mitochondrial function are associated with kidney disease in people with Type 1 diabetes. <i>Diabetic Medicine</i> , 2015 , 32, 1104-9	3.5	11
264	Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment. <i>Diabetic Medicine</i> , 2015 , 32, 343-52	3.5	49
263	Vitamin D analogue therapy, cardiovascular risk and kidney function in people with Type 1 diabetes mellitus and diabetic nephropathy: a randomized trial. <i>Diabetic Medicine</i> , 2015 , 32, 374-81	3.5	26
262	Increased all-cause mortality in patients with type 1 diabetes and high-expression mannan-binding lectin genotypes: a 12-year follow-up study. <i>Diabetes Care</i> , 2015 , 38, 1898-903	14.6	14

261	IGFBP-4 Fragments as Markers of Cardiovascular Mortality in Type 1 Diabetes Patients With and Without Nephropathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 3032-40	5.6	22
260	Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 314, 884-94	27.4	342
259	The influence of pharmaceutically induced weight changes on estimates of renal function: A patient-level pooled analysis of seven randomised controlled trials of glucose lowering medication. <i>Journal of Diabetes and Its Complications</i> , 2015 , 29, 1146-51	3.2	9
258	SORBS1 gene, a new candidate for diabetic nephropathy: results from a multi-stage genome-wide association study in patients with type 1 diabetes. <i>Diabetologia</i> , 2015 , 58, 543-8	10.3	28
257	Diabetic nephropathy in 2014: improved cardiorenal prognosis in diabetic nephropathy. <i>Nature Reviews Nephrology</i> , 2015 , 11, 68-70	14.9	12
256	Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes. <i>Journal of Internal Medicine</i> , 2015 , 277, 362-371	10.8	50
255	PP.33.31. <i>Journal of Hypertension</i> , 2015 , 33, e437	1.9	
254	Diabetic kidney disease. <i>Nature Reviews Disease Primers</i> , 2015 , 1, 15018	51.1	241
253	Additive prognostic value of plasma N-terminal pro-brain natriuretic peptide and coronary artery calcification for cardiovascular events and mortality in asymptomatic patients with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2015 , 14, 59	8.7	28
252	PP.33.30. <i>Journal of Hypertension</i> , 2015 , 33, e436-e437	1.9	
251	Effect of 4 years subcutaneous insulin infusion treatment on albuminuria, kidney function and HbA1c compared with multiple daily injections: a longitudinal follow-up study. <i>Diabetic Medicine</i> , 2015 , 32, 1445-52	3.5	18
250	Plasma proteomics classifiers improve risk prediction for renal disease in patients with hypertension or type 2 diabetes. <i>Journal of Hypertension</i> , 2015 , 33, 2123-32	1.9	21
249	The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers. <i>British Journal of Clinical Pharmacology</i> , 2015 , 80, 678-86	3.8	32
248	Cuff inflations do not affect night-time blood pressure: comparison of 24 h ambulatory blood pressure measured by a cuff and a tonometric device in type 2 diabetes. <i>Blood Pressure Monitoring</i> , 2015 , 20, 369-72	1.3	2
247	Characterization of renal biomarkers for use in clinical trials: effect of preanalytical processing and qualification using samples from subjects with diabetes. <i>Drug Design, Development and Therapy</i> , 2015 , 9, 3191-8	4.4	12
246	Elevated Urinary Connective Tissue Growth Factor in Diabetic Nephropathy Is Caused by Local Production and Tubular Dysfunction. <i>Journal of Diabetes Research</i> , 2015 , 2015, 539787	3.9	17
245	Effect of Sensor-Augmented Pump Treatment Versus Multiple Daily Injections on Albuminuria: A 1-Year Randomized Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 4181-8	5.6	15
244	Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides. <i>Journal of the American Society of Nephrology: JASN</i> , 2015 , 26, 1999-2010	12.7	164

243	Microalbuminuria: a parameter that has changed diabetes care. <i>Diabetes Research and Clinical Practice</i> , 2015 , 107, 1-8	7.4	58
242	Identification of possible adverse drug reactions in clinical notes: The case of glucose-lowering medicines. <i>Journal of Research in Pharmacy Practice</i> , 2015 , 4, 64-72	1.3	6
241	Prevalence of systolic and diastolic dysfunction in patients with type 1 diabetes without known heart disease: the Thousand & 1 Study. <i>Diabetologia</i> , 2014 , 57, 672-80	10.3	59
240	Association of the pattern recognition molecule H-ficolin with incident microalbuminuria in an inception cohort of newly diagnosed type 1 diabetic patients: an 18 year follow-up study. <i>Diabetologia</i> , 2014 , 57, 2201-7	10.3	19
239	Urine and plasma metabolites predict the development of diabetic nephropathy in individuals with Type 2 diabetes mellitus. <i>Diabetic Medicine</i> , 2014 , 31, 1138-47	3.5	94
238	Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2014 , 29, 1563-70	4.3	94
237	Improved survival and renal prognosis of patients with type 2 diabetes and nephropathy with improved control of risk factors. <i>Diabetes Care</i> , 2014 , 37, 1660-7	14.6	50
236	Sequential RAAS blockade: is it worth the risk?. <i>Advances in Chronic Kidney Disease</i> , 2014 , 21, 159-65	4.7	8
235	Urinary alpha- and pi-glutathione s-transferases in adult patients with type 1 diabetes. <i>Nephron Extra</i> , 2014 , 4, 127-33		3
234	Glomerular filtration rate estimation using cystatin C alone or combined with creatinine as a confirmatory test. <i>Nephrology Dialysis Transplantation</i> , 2014 , 29, 1195-203	4.3	64
233	Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. <i>American Journal of Nephrology</i> , 2014 , 40, 572-81	4.6	27
232	Pulse wave reflection is associated with diabetes duration, albuminuria and cardiovascular disease in type 1 diabetes. <i>Acta Diabetologica</i> , 2014 , 51, 973-80	3.9	6
231	Treatment with continuous subcutaneous insulin infusion is associated with lower arterial stiffness. <i>Acta Diabetologica</i> , 2014 , 51, 955-62	3.9	8
230	Central hemodynamics are associated with cardiovascular disease and albuminuria in type 1 diabetes. <i>American Journal of Hypertension</i> , 2014 , 27, 1152-9	2.3	17
229	Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia. <i>BMJ Open Diabetes Research and Care</i> , 2014 , 2, e000011	4.5	21
228	Cause-specific mortality according to urine albumin creatinine ratio in the general population. <i>PLoS ONE</i> , 2014 , 9, e93212	3.7	6
227	Common variant in the HMG2 gene increases susceptibility to nephropathy in patients with type 2 diabetes. <i>Diabetologia</i> , 2013 , 56, 323-9	10.3	19
226	Vitamin D status and 5-year changes in urine albumin creatinine ratio and parathyroid hormone in a general population. <i>Endocrine</i> , 2013 , 44, 473-80	4	22

225	The methylglyoxal-derived AGE tetrahydropyrimidine is increased in plasma of individuals with type 1 diabetes mellitus and in atherosclerotic lesions and is associated with sVCAM-1. <i>Diabetologia</i> , 2013 , 56, 1845-55	10.3	34
224	Exome sequencing-driven discovery of coding polymorphisms associated with common metabolic phenotypes. <i>Diabetologia</i> , 2013 , 56, 298-310	10.3	102
223	Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study. <i>Current Diabetes Reports</i> , 2013 , 13, 550-9	5.6	120
222	Arterial stiffness is associated with cardiovascular, renal, retinal, and autonomic disease in type 1 diabetes. <i>Diabetes Care</i> , 2013 , 36, 715-21	14.6	78
221	Serum amyloid A and C-reactive protein levels may predict microalbuminuria and macroalbuminuria in newly diagnosed type 1 diabetic patients. <i>Journal of Diabetes and Its Complications</i> , 2013 , 27, 59-63	3.2	15
220	24-hour central aortic systolic pressure and 24-hour central pulse pressure are related to diabetic complications in type 1 diabetes - a cross-sectional study. <i>Cardiovascular Diabetology</i> , 2013 , 12, 122	8.7	22
219	Improving peptide relative quantification in MALDI-TOF MS for biomarker assessment. <i>Proteomics</i> , 2013 , 13, 2967-75	4.8	17
218	Effects of 12 weeks treatment with a proton pump inhibitor on insulin secretion, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind prospective placebo-controlled study. <i>Diabetologia</i> , 2013 , 56, 22-30	10.3	32
217	Urinary adiponectin excretion rises with increasing albuminuria in type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2013 , 27, 604-8	3.2	15
216	Diabetic nephropathy: Could problems with bardoxolone methyl have been predicted?. <i>Nature Reviews Nephrology</i> , 2013 , 9, 128-30	14.9	23
215	A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus. <i>Diabetologia</i> , 2013 , 56, 259-67	10.3	117
214	Can ADAMTS13 lead us to the paradise of personalized medicine?. <i>Diabetes</i> , 2013 , 62, 3331-2	0.9	1
213	RNA oxidation and albuminuria in type 1 diabetes patients. <i>Cardiovascular Endocrinology</i> , 2013 , 2, 103-105		
212	Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2013 , 14, 161-6	3	18
211	Tonometric devices for central aortic systolic pressure measurements in patients with type 1 diabetes: comparison of the BPro and SphygmoCor devices. <i>Blood Pressure Monitoring</i> , 2013 , 18, 156-60	1.3	10
210	Urinary sulphate excretion and progression of diabetic nephropathy in Type 1 diabetes. <i>Diabetic Medicine</i> , 2013 , 30, 563-6	3.5	12
209	Diabetes mellitus, hypertension and albuminuria in rural Zambia: a hospital-based survey. <i>Tropical Medicine and International Health</i> , 2013 , 18, 1080-1084	2.3	10
208	Urinary renin and angiotensinogen in type 2 diabetes: added value beyond urinary albumin?. <i>Journal of Hypertension</i> , 2013 , 31, 1646-52	1.9	23

207	Direct renin inhibition in chronic kidney disease. <i>British Journal of Clinical Pharmacology</i> , 2013 , 76, 580-63.8	8
206	Implementation of proteomic biomarkers: making it work. <i>European Journal of Clinical Investigation</i> , 2012 , 42, 1027-36	4.6 131
205	Evaluation of placental growth factor and soluble Fms-like tyrosine kinase 1 as predictors of all-cause and cardiovascular mortality in patients with Type 1 diabetes with and without diabetic nephropathy. <i>Diabetic Medicine</i> , 2012 , 29, 337-44	3.5 13
204	Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. <i>Diabetic Medicine</i> , 2012 , 29, e184-90.5	61
203	Arterial stiffness and endothelial dysfunction independently and synergistically predict cardiovascular and renal outcome in patients with type 1 diabetes. <i>Diabetic Medicine</i> , 2012 , 29, 990-4	3.5 30
202	NT-proBNP, echocardiographic abnormalities and subclinical coronary artery disease in high risk type 2 diabetic patients. <i>Cardiovascular Diabetology</i> , 2012 , 11, 19	8.7 11
201	Discrepancy between tonometric ambulatory and cuff-based office blood pressure measurements in patients with type 1 diabetes. <i>Journal of Clinical Hypertension</i> , 2012 , 14, 686-93	2.3 2
200	Urinary proteomics for early diagnosis in diabetic nephropathy. <i>Diabetes</i> , 2012 , 61, 3304-13	0.9 191
199	Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. <i>Lancet, The</i> , 2012 , 380, 1649-61	40 301
198	Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. <i>Lancet, The</i> , 2012 , 380, 1662-73	40 664
197	Ambulatory tonometric blood pressure measurements in patients with diabetes. <i>Diabetes Technology and Therapeutics</i> , 2012 , 14, 453-6	8.1 21
196	Higher plasma high-mobility group box 1 levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12 year follow-up study. <i>Diabetologia</i> , 2012 , 55, 2489-93	10.3 27
195	High YKL-40 levels predict mortality in patients with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2012 , 96, 84-9	7.4 35
194	Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients. <i>Diabetes Research and Clinical Practice</i> , 2012 , 97, 71-6	7.4 62
193	Plasma NT-proBNP and white matter hyperintensities in type 2 diabetic patients. <i>Cardiovascular Diabetology</i> , 2012 , 11, 119	8.7 11
192	Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria. <i>Amino Acids</i> , 2012 , 42, 1627-39	3.5 19
191	New susceptibility loci associated with kidney disease in type 1 diabetes. <i>PLoS Genetics</i> , 2012 , 8, e1002921	176
190	Impact of glycaemic control on the effect of direct renin inhibition in the AVOID study. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2012 , 13, 250-3	3 2

189	Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2012 , 13, 118-21	3	19
188	The effect of RAAS blockade on markers of renal tubular damage in diabetic nephropathy: u-NGAL, u-KIM1 and u-LFABP. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2012 , 72, 137-42	2	15
187	Cardiovascular autonomic neuropathy and subclinical cardiovascular disease in normoalbuminuric type 1 diabetic patients. <i>Diabetes</i> , 2012 , 61, 1822-30	0.9	32
186	Vitamin D levels and asymptomatic coronary artery disease in type 2 diabetic patients with elevated urinary albumin excretion rate. <i>Diabetes Care</i> , 2012 , 35, 168-72	14.6	40
185	Serum uric acid as a new player in the development of diabetic nephropathy. <i>Journal of Renal Nutrition</i> , 2011 , 21, 124-7	3	49
184	Omics-bioinformatics in the context of clinical data. <i>Methods in Molecular Biology</i> , 2011 , 719, 479-97	1.4	13
183	NT-proBNP levels, atherosclerosis and vascular function in asymptomatic type 2 diabetic patients with microalbuminuria: peripheral reactive hyperaemia index but not NT-proBNP is an independent predictor of coronary atherosclerosis. <i>Cardiovascular Diabetology</i> , 2011 , 10, 71	8.7	25
182	Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. <i>Kidney International</i> , 2011 , 79, 1331-40	9.9	468
181	The Baltic Sea: Estimates of total fisheries removals 1950-2007. <i>Fisheries Research</i> , 2011 , 108, 356-363	2.3	63
180	Fibulin-1 is a marker for arterial extracellular matrix alterations in type 2 diabetes. <i>Clinical Chemistry</i> , 2011 , 57, 1556-65	5.5	58
179	Experimental testing of skin reactions to insulin detemir in diabetes patients naïve to insulin detemir. <i>Skin Research and Technology</i> , 2011 , 17, 411-9	1.9	1
178	The CTGF -945GC polymorphism is not associated with plasma CTGF and does not predict nephropathy or outcome in type 1 diabetes. <i>Journal of Negative Results in BioMedicine</i> , 2011 , 10, 4		7
177	Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial. <i>Nephrology Dialysis Transplantation</i> , 2011 , 26, 3573-7	4.3	5
176	Initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trial. <i>Diabetes Care</i> , 2011 , 34, 2078-83	14.6	48
175	Endothelial progenitor cells in long-standing asymptomatic type 1 diabetic patients with or without diabetic nephropathy. <i>Nephron Clinical Practice</i> , 2011 , 118, c309-14		6
174	Urinary neutrophil gelatinase-associated lipocalin and progression of diabetic nephropathy in type 1 diabetic patients in a four-year follow-up study. <i>Nephron Clinical Practice</i> , 2011 , 118, c130-5		18
173	Elevated NT-proBNP and coronary calcium score in relation to coronary artery disease in asymptomatic type 2 diabetic patients with elevated urinary albumin excretion rate. <i>Nephrology Dialysis Transplantation</i> , 2011 , 26, 3242-9	4.3	22
172	Long-term effects of Irbesartan treatment and smoking on nucleic acid oxidation in patients with type 2 diabetes and microalbuminuria: an Irbesartan in patients with type 2 diabetes and Microalbuminuria (IRMA 2) substudy. <i>Diabetes Care</i> , 2011 , 34, 1192-8	14.6	8

171	Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. <i>Diabetes Care</i> , 2011 , 34, 442-7	14.6	167
170	Need for better diabetes treatment for improved renal outcome. <i>Kidney International</i> , 2011 , S28-32	9.9	41
169	Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy. <i>Kidney International</i> , 2011 , 79, 1113-8	9.9	81
168	Vitamin D levels, microvascular complications, and mortality in type 1 diabetes. <i>Diabetes Care</i> , 2011 , 34, 1081-5	14.6	76
167	Osteoprotegerin and coronary artery disease in type 2 diabetic patients with microalbuminuria. <i>Cardiovascular Diabetology</i> , 2011 , 10, 70	8.7	10
166	Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011 , 6, 1025-31	6.9	46
165	Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril. <i>Diabetic Medicine</i> , 2010 , 27, 1144-50	3.5	83
164	Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy. <i>PLoS ONE</i> , 2010 , 5, e13421	3.7	104
163	Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy. <i>Diabetes Care</i> , 2010 , 33, 2304-9	14.6	49
162	Osteoprotegerin and mortality in type 2 diabetic patients. <i>Diabetes Care</i> , 2010 , 33, 2561-6	14.6	43
161	Plasma growth differentiation factor-15 independently predicts all-cause and cardiovascular mortality as well as deterioration of kidney function in type 1 diabetic patients with nephropathy. <i>Diabetes Care</i> , 2010 , 33, 1567-72	14.6	75
160	Higher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. <i>Diabetes</i> , 2010 , 59, 2027-32	0.9	92
159	Vitamin D levels and mortality in type 2 diabetes. <i>Diabetes Care</i> , 2010 , 33, 2238-43	14.6	101
158	Soluble CD40 ligand is elevated in type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function. <i>Platelets</i> , 2010 , 21, 525-32	3.6	25
157	Development and validation of GFR-estimating equations using diabetes, transplant and weight. <i>Nephrology Dialysis Transplantation</i> , 2010 , 25, 449-57	4.3	90
156	Proteomic biomarkers in diabetic nephropathy--reality or future promise?. <i>Nephrology Dialysis Transplantation</i> , 2010 , 25, 2843-5	4.3	28
155	Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients. <i>Diabetes Care</i> , 2010 , 33, 1320-4	14.6	85
154	Recommendations for biomarker identification and qualification in clinical proteomics. <i>Science Translational Medicine</i> , 2010 , 2, 46ps42	17.5	237

153	Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals. <i>Journal of Hypertension</i> , 2010 , 28, 2316-22	1.9	99
152	Telomere length predicts all-cause mortality in patients with type 1 diabetes. <i>Diabetologia</i> , 2010 , 53, 45-8	10.3	61
151	Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial. <i>Diabetologia</i> , 2010 , 53, 1576-80	10.3	26
150	Multifactorial treatment increases endothelial progenitor cells in patients with type 2 diabetes. <i>Diabetologia</i> , 2010 , 53, 2129-33	10.3	28
149	A polymorphism in the gene encoding carnosinase (CNDP1) as a predictor of mortality and progression from nephropathy to end-stage renal disease in type 1 diabetes mellitus. <i>Diabetologia</i> , 2010 , 53, 2562-8	10.3	19
148	Quantitative iTRAQ-Based Proteomic Identification of Candidate Biomarkers for Diabetic Nephropathy in Plasma of Type 1 Diabetic Patients. <i>Clinical Proteomics</i> , 2010 , 6, 105-114	5	26
147	Plasma proteome analysis of patients with type 1 diabetes with diabetic nephropathy. <i>Proteome Science</i> , 2010 , 8, 4	2.6	33
146	Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria. <i>BMC Nephrology</i> , 2010 , 11, 29	2.7	61
145	Finding diabetic nephropathy biomarkers in the plasma peptidome by high-throughput magnetic bead processing and MALDI-TOF-MS analysis. <i>Proteomics - Clinical Applications</i> , 2010 , 4, 697-705	3.1	18
144	Urinary collagen fragments are significantly altered in diabetes: a link to pathophysiology. <i>PLoS ONE</i> , 2010 , 5, e13051	3.7	44
143	Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. <i>Diabetes Care</i> , 2009 , 32, 1873-9	14.6	124
142	Tubular and glomerular injury in diabetes and the impact of ACE inhibition. <i>Diabetes Care</i> , 2009 , 32, 1684-9	14.6	54
141	Follow-up of intensive glucose control in type 2 diabetes. <i>New England Journal of Medicine</i> , 2009 , 360, 416; author reply 418	59.2	9
140	Autoregulation of glomerular filtration rate during spironolactone treatment in hypertensive patients with type 1 diabetes: a randomized crossover trial. <i>Nephrology Dialysis Transplantation</i> , 2009 , 24, 3343-9	4.3	10
139	YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria. <i>Diabetes Care</i> , 2009 , 32, 323-8	14.6	107
138	Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial. <i>Diabetologia</i> , 2009 , 52, 46-9	10.3	24
137	Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2009 , 11, 966-77	6.7	33
136	Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study. <i>Diabetes</i> , 2009 , 58, 1668-71	0.9	163

135	Nephropathy in type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity. <i>Platelets</i> , 2009 , 20, 513-9	3.6	23
134	Is renal Na ⁺ ,K ⁺ -ATPase a new target for renin-angiotensin blocking agents in diabetic nephropathy?. <i>Journal of Physiology</i> , 2008 , 586, 5283	3.9	0
133	Elevated levels of high-molecular-weight adiponectin in type 1 diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 3186-91	5.6	60
132	Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. <i>Kidney International</i> , 2008 , 73, 1419-25	9.9	102
131	Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. <i>Diabetes Care</i> , 2008 , 31, 747-52	14.6	102
130	Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: association with mortality and decline of glomerular filtration rate. <i>Diabetes Care</i> , 2008 , 31, 1170-6	14.6	93
129	Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy. <i>Diabetes Care</i> , 2008 , 31, 1177-82	14.6	87
128	Urinary proteomics in diabetes and CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2008 , 19, 1283-90	12.7	235
127	ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2008 , 19, 771-9	12.7	63
126	Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type 1 diabetes and diabetic nephropathy. <i>Kidney International</i> , 2008 , 74, 649-54	9.9	110
125	Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2008 , 68, 731-8	2	66
124	Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study. <i>PLoS ONE</i> , 2008 , 3, e3363	3.7	64
123	Long-term prevention of diabetic nephropathy: an audit. <i>Diabetologia</i> , 2008 , 51, 956-61	10.3	16
122	Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy. <i>Diabetologia</i> , 2008 , 51, 2100-7	10.3	57
121	The urinary proteome in diabetes and diabetes-associated complications: New ways to assess disease progression and evaluate therapy. <i>Proteomics - Clinical Applications</i> , 2008 , 2, 997-1007	3.1	60
120	Pregnancy-associated plasma protein A in a large cohort of Type 1 diabetic patients with and without diabetic nephropathy-a prospective follow-up study. <i>Diabetic Medicine</i> , 2007 , 24, 1381-5	3.5	10
119	Predictors of mortality in patients with type 2 diabetes with or without diabetic nephropathy: a follow-up study. <i>Journal of Hypertension</i> , 2007 , 25, 2479-85	1.9	74
118	Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005. <i>Diabetologia</i> , 2006 , 49, 11-9	10.3	65

117	Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history. <i>Current Diabetes Reports</i> , 2006 , 6, 479-83	5.6	123
116	Impact of renin angiotensin system blockade on night to day blood pressure ratio in diabetic nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2006 , 21, 2030-1	4.3	3
115	Aldosterone synthase (CYP11B2)-344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2006 , 66, 173-80	2	6
114	Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy. <i>Diabetes</i> , 2006 , 55, 3550-5	0.9	66
113	Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in type 2 diabetes. <i>Diabetes Care</i> , 2006 , 29, 747-8; author reply 748-9	14.6	2
112	Cardiac autonomic neuropathy predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. <i>Diabetes Care</i> , 2006 , 29, 334-9	14.6	125
111	Renoprotective effects of renin-angiotensin-system inhibitors. <i>Lancet, The</i> , 2006 , 367, 898-9; author reply 900-2	4.0	3
110	Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. <i>Kidney International</i> , 2006 , 70, 536-42	9.9	145
109	Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathy. <i>Kidney International</i> , 2005 , 67, 2325-9	9.9	34
108	Improved prognosis in type 1 diabetic patients with nephropathy: a prospective follow-up study. <i>Kidney International</i> , 2005 , 68, 1250-7	9.9	50
107	Progression of microalbuminuria in type 1 diabetes: ten-year prospective observational study. <i>Kidney International</i> , 2005 , 68, 1446-50	9.9	49
106	Beneficial impact of spironolactone in diabetic nephropathy. <i>Kidney International</i> , 2005 , 68, 2829-36	9.9	164
105	Renoprotection with and without blood pressure reduction. <i>Kidney International</i> , 2005 , S54-9	9.9	13
104	The changing epidemiology of diabetic microangiopathy in type 1 diabetes. <i>Diabetologia</i> , 2005 , 48, 1439-44	14.3	59
103	Oral contraceptives, angiotensin-dependent renal vasoconstriction, and risk of diabetic nephropathy. <i>Diabetes Care</i> , 2005 , 28, 1988-94	14.6	68
102	Improved survival in patients obtaining remission of nephrotic range albuminuria in diabetic nephropathy. <i>Kidney International</i> , 2004 , 66, 1180-6	9.9	24
101	Progression of nephropathy in type 2 diabetic patients. <i>Kidney International</i> , 2004 , 66, 1596-605	9.9	217
100	Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. <i>Diabetologia</i> , 2004 , 47, 1936-9	10.3	169

99	Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. <i>BMJ, The</i> , 2004 , 328, 1105	5.9	270
98	Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points. <i>Seminars in Nephrology</i> , 2004 , 24, 147-57	4.8	46
97	Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2003 , 18, 293-7	4.3	19
96	Birth weight--a risk factor for progression in diabetic nephropathy?. <i>Journal of Internal Medicine</i> , 2003 , 253, 343-50	10.8	15
95	Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?. <i>Diabetes Care</i> , 2003 , 26, 1501-6	14.6	48
94	Smoking and progression of diabetic nephropathy in type 1 diabetes. <i>Diabetes Care</i> , 2003 , 26, 911-6	14.6	44
93	Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. <i>Diabetes Care</i> , 2003 , 26, 1258-64	14.6	279
92	Pregnancy and progression of diabetic nephropathy. <i>Diabetologia</i> , 2002 , 45, 36-41	10.3	92
91	Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?. <i>Kidney International</i> , 2002 , 62, 192-8	9.9	24
90	Optimal dose of losartan for renoprotection in diabetic nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2002 , 17, 1413-8	4.3	47
89	Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study. <i>Diabetes Care</i> , 2002 , 25, 859-64	14.6	184
88	Role of Plasma Homocysteine and Plasminogen Activator Inhibitor-1 in the Progression of Diabetic Nephropathy 2002 , 97-101		
87	Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively. <i>Kidney International</i> , 2001 , 60, 277-83	9.9	66
86	Progression of diabetic nephropathy. <i>Kidney International</i> , 2001 , 59, 702-9	9.9	216
85	Prolonged QTc interval predicts mortality in patients with Type 1 diabetes mellitus. <i>Diabetic Medicine</i> , 2001 , 18, 199-205	3.5	129
84	Preventing diabetic nephropathy: an audit. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2001 , 61, 471-7	2	5
83	Lack of effect of fish oil supplementation on coagulation and transcapillary escape rate of albumin in insulin-dependent diabetic patients with diabetic nephropathy. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2001 , 61, 349-56	2	15
82	Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. <i>Diabetes Care</i> , 2001 , 24, 177-80	14.6	9

81	Remission of nephrotic-range albuminuria in type 1 diabetic patients. <i>Diabetes Care</i> , 2001 , 24, 1972-7	14.6	53
80	Progression of diabetic nephropathy: role of plasma homocysteine and plasminogen activator inhibitor-1. <i>American Journal of Kidney Diseases</i> , 2001 , 38, 1376-80	7.4	22
79	Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. <i>Kidney International</i> , 2000 , 57, 601-6	9.9	197
78	Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. <i>Kidney International</i> , 2000 , 57, S32-S37	9.9	29
77	Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy. <i>Diabetes Care</i> , 2000 , 23, 1725-30	14.6	57
76	Cardiovascular morbidity and early mortality cluster in parents of type 1 diabetic patients with diabetic nephropathy. <i>Diabetes Care</i> , 2000 , 23, 30-3	14.6	41
75	QTc interval length and QT dispersion as predictors of mortality in patients with non-insulin-dependent diabetes. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2000 , 60, 323-32	2	74
74	Serum Creatinine and Other Measures of GFR in Diabetes 2000 , 95-101		
73	Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. <i>Kidney International, Supplement</i> , 2000 , 75, S32-7		9
72	Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up study. <i>Diabetes Care</i> , 1999 , 22, 478-83	14.6	65
71	Natural course of kidney function in Type 2 diabetic patients with diabetic nephropathy. <i>Diabetic Medicine</i> , 1999 , 16, 388-94	3.5	13
70	Increased sympathetic activity during sleep and nocturnal hypertension in Type 2 diabetic patients with diabetic nephropathy. <i>Diabetic Medicine</i> , 1999 , 16, 555-62	3.5	59
69	Progression of diabetic nephropathy in normotensive type 1 diabetic patients. <i>Kidney International</i> , 1999 , 71, S101-5	9.9	71
68	Concentration changes during venous occlusion of proteins with affinity for extracellular matrix in insulin-dependent diabetes mellitus a sign of vascular damage in patients with diabetic nephropathy?. <i>Fibrinolysis and Proteolysis</i> , 1999 , 13, 142-147		
67	Effects of nisoldipine and lisinopril on left ventricular mass and function in diabetic nephropathy. <i>Diabetes Care</i> , 1999 , 22, 491-4	14.6	10
66	Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. <i>Kidney International</i> , 1998 , 53, 1002-6	9.9	71
65	Promotion, prediction and prevention of progression of nephropathy in type 1 diabetes mellitus. <i>Diabetic Medicine</i> , 1998 , 15, 900-19	3.5	44
64	Improved visual function in IDDM patients with unchanged cumulative incidence of sight-threatening diabetic retinopathy. <i>Diabetes Care</i> , 1998 , 21, 2007-15	14.6	24

63	Diabetes and risk of adverse events with calcium antagonists. <i>Diabetes Care</i> , 1998 , 21, 1779-80	14.6	8
62	Assessment of glomerular filtration rate in diabetic nephropathy using the plasma clearance of ⁵¹ Cr-EDTA. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1998 , 58, 405-13	2	9
61	Effects of nisoldipine and lisinopril on microvascular dysfunction in hypertensive Type I diabetes patients with nephropathy. <i>Clinical Science</i> , 1998 , 95, 709-17	6.5	6
60	Serum Creatinine and other Measures of GFR in Diabetes 1998 , 97-102		
59	Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. <i>Diabetes</i> , 1997 , 46, 1182-8	0.9	130
58	Polymorphisms in the interleukin-1 gene cluster do not contribute to the genetic susceptibility of diabetic nephropathy in Caucasian patients with IDDM. <i>Diabetes</i> , 1997 , 46, 1075-6	0.9	22
57	Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. <i>Diabetes</i> , 1997 , 46, 481-7	0.9	53
56	Lisinopril improves endothelial dysfunction in hypertensive NIDDM subjects with diabetic nephropathy. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1997 , 57, 427-34	2	29
55	Renal protection in diabetes--an emerging role for calcium antagonists. <i>Cardiology</i> , 1997 , 88 Suppl 3, 56-62	1.6	9
54	Left ventricular hypertrophy in non-insulin-dependent diabetic patients with and without diabetic nephropathy. <i>Diabetic Medicine</i> , 1997 , 14, 538-46	3.5	35
53	Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. <i>Diabetes</i> , 1997 , 46, 481-487	0.9	19
52	Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. <i>Diabetes</i> , 1997 , 46, 1182-1188	0.9	51
51	Angiotensin-II type 1 receptor gene polymorphism and diabetic microangiopathy. <i>Nephrology Dialysis Transplantation</i> , 1996 , 11, 1019-1023	4.3	32
50	Fibrinolysis in insulin-dependent diabetic patients with and without nephropathy. <i>Fibrinolysis</i> , 1996 , 10, 331-335		6
49	Elevated fibrinogen and the relation to acute phase response in diabetic nephropathy. <i>Thrombosis Research</i> , 1996 , 81, 485-90	8.2	48
48	Renal protection in diabetes: an emerging role for calcium antagonists. <i>Journal of Hypertension</i> , 1996 , 14, S21-5	1.9	19
47	Angiotensin-II type 1 receptor gene polymorphism and diabetic microangiopathy. <i>Nephrology Dialysis Transplantation</i> , 1996 , 11, 1019-1023	4.3	6
46	Macro-microangiopathy and endothelial dysfunction in NIDDM patients with and without diabetic nephropathy. <i>Diabetologia</i> , 1996 , 39, 1590-7	10.3	65

45	Benefits of long-term antihypertensive treatment on prognosis in diabetic nephropathy. <i>Kidney International</i> , 1996 , 49, 1778-82	9.9	47
44	Circadian rhythm of arterial blood pressure and albuminuria in diabetic nephropathy. <i>Kidney International</i> , 1996 , 50, 579-85	9.9	40
43	Prevention and treatment of diabetic nephropathy with blood pressure lowering drugs. <i>Nephrology</i> , 1996 , 2, s45-s48	2.2	
42	Fish oil in diabetic nephropathy. <i>Diabetes Care</i> , 1996 , 19, 1214-9	14.6	44
41	Increased plasma apolipoprotein (a) levels in IDDM patients with diabetic nephropathy. <i>Diabetes Care</i> , 1996 , 19, 1382-7	14.6	16
40	Increased tissue factor pathway inhibitor activity in IDDM patients with nephropathy. <i>Diabetes Care</i> , 1996 , 19, 441-5	14.6	27
39	Angiotensinogen gene polymorphisms in IDDM patients with diabetic nephropathy. <i>Diabetes</i> , 1996 , 45, 367-369	0.9	54
38	Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study. <i>BMJ: British Medical Journal</i> , 1996 , 313, 591-4		128
37	Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study. <i>BMJ: British Medical Journal</i> , 1996 , 313, 779-84		314
36	Angiotensinogen gene polymorphisms in IDDM patients with diabetic nephropathy. <i>Diabetes</i> , 1996 , 45, 367-369	0.9	12
35	Procoagulant activity and intimal dysfunction in IDDM. <i>Diabetologia</i> , 1995 , 38, 73-8	10.3	22
34	Increased glomerular filtration rate after withdrawal of long-term antihypertensive treatment in diabetic nephropathy. <i>Kidney International</i> , 1995 , 47, 1726-31	9.9	60
33	Low birth weight. A risk factor for development of diabetic nephropathy?. <i>Diabetes</i> , 1995 , 44, 1405-7	0.9	74
32	Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. <i>Diabetes</i> , 1995 , 44, 489-94	0.9	165
31	Unchanged incidence of diabetic nephropathy in IDDM patients. <i>Diabetes</i> , 1995 , 44, 739-43	0.9	97
30	On the mechanisms of blunted nocturnal decline in arterial blood pressure in NIDDM patients with diabetic nephropathy. <i>Diabetes</i> , 1995 , 44, 783-9	0.9	80
29	Angiotensin-converting enzyme inhibition in diabetic nephropathy: ten years experience. <i>American Journal of Kidney Diseases</i> , 1995 , 26, 99-107	7.4	85
28	Insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene is associated with coronary heart disease in IDDM patients with diabetic nephropathy. <i>Diabetologia</i> , 1995 , 38, 798-803	10.3	79

27	Short stature and diabetic nephropathy. <i>BMJ: British Medical Journal</i> , 1995 , 310, 296-7		49
26	Low birth weight. A risk factor for development of diabetic nephropathy?. <i>Diabetes</i> , 1995 , 44, 1405-1407	0.9	18
25	Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. <i>Diabetes</i> , 1995 , 44, 489-494	0.9	48
24	Unchanged incidence of diabetic nephropathy in IDDM patients. <i>Diabetes</i> , 1995 , 44, 739-743	0.9	27
23	On the mechanisms of blunted nocturnal decline in arterial blood pressure in NIDDM patients with diabetic nephropathy. <i>Diabetes</i> , 1995 , 44, 783-789	0.9	23
22	Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. <i>Diabetes</i> , 1994 , 43, 1108-13	0.9	47
21	Prevalence of arterial hypertension in diabetic patients before and after the JNC-V. <i>Diabetes Care</i> , 1994 , 17, 1247-51	14.6	128
20	Glomerular size- and charge selectivity in type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy. <i>Diabetologia</i> , 1994 , 37, 195-201	10.3	30
19	Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. <i>Diabetologia</i> , 1994 , 37, 511-6	10.3	158
18	Monitoring kidney function in diabetic nephropathy. <i>Diabetologia</i> , 1994 , 37, 708-12	10.3	22
17	The effect of the relationship between tissue-type plasminogen activator and plasminogen activator inhibitor type 1 on tissue-type plasminogen activator activity in insulin-dependent diabetes mellitus. <i>Fibrinolysis</i> , 1994 , 8, 22-24		33
16	The use of antihypertensive agents in prevention and treatment of diabetic nephropathy. <i>Current Opinion in Nephrology and Hypertension</i> , 1994 , 3, 292-300	3.5	38
15	Reduction in albuminuria predicts diminished progression in diabetic nephropathy. <i>Kidney International, Supplement</i> , 1994 , 45, S145-9		16
14	Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. <i>Diabetes</i> , 1994 , 43, 1108-1113	0.9	21
13	Monitoring kidney function in diabetic nephropathy. <i>Diabetologia</i> , 1994 , 37, 708-712	10.3	
12	Calcium antagonists and the diabetic hypertensive patient. <i>American Journal of Kidney Diseases</i> , 1993 , 21, 47-52	7.4	6
11	Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy. <i>American Journal of Kidney Diseases</i> , 1993 , 22, 188-95	7.4	87
10	Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients. <i>Diabetes</i> , 1993 , 42, 715-9	0.9	117

9	Apolipoprotein(a) and cardiovascular disease in type 2 (non-insulin-dependent) diabetic patients with and without diabetic nephropathy. <i>Diabetologia</i> , 1993 , 36, 438-44	10.3	43
8	Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients. <i>Diabetes</i> , 1993 , 42, 715-719	0.9	35
7	Apolipoprotein(a) in insulin-dependent diabetic patients with and without diabetic nephropathy. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1992 , 52, 513-21	2	26
6	Placebo-controlled comparison of captopril, metoprolol, and hydrochlorothiazide therapy in non-insulin-dependent diabetic patients with primary hypertension. <i>American Journal of Hypertension</i> , 1992 , 5, 257-65	2.3	16
5	Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy. <i>Diabetologia</i> , 1992 , 35, 447-51	10.3	78
4	Red cell Na ⁺ /Li ⁺ countertransport in non-insulin-dependent diabetics with diabetic nephropathy. <i>Kidney International</i> , 1991 , 39, 135-40	9.9	22
3	Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulin-dependent) diabetic patients. <i>Diabetologia</i> , 1991 , 34, 655-61	10.3	293
2	Replication and cross-validation of T2D subtypes based on clinical variables: an IMI-RHAPSODY study		1
1	Genome-wide association study of diabetic kidney disease highlights biology involved in renal basement membrane collagen		2